Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson's disease

Salama,Mohamed; Sobh,Mahmoud; Emam,Mahmoud; Abdalla,Ahmed; Sabry,Dina; El‑Gamal,Mohamed; Lotfy,Ahmed; El‑Husseiny,Mahmoud; Sobh,Mohamed; Shalash,Ali; Mohamed,Wael  My

doi:10.3892/etm.2017.4073

Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson's disease

Authors:
- Mohamed Salama
- Mahmoud Sobh
- Mahmoud Emam
- Ahmed Abdalla
- Dina Sabry
- Mohamed El‑Gamal
- Ahmed Lotfy
- Mahmoud El‑Husseiny
- Mohamed Sobh
- Ali Shalash
- Wael My Mohamed
View Affiliations

Affiliations: Medical Experimental Research Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt, Neurology Department, Ain Shams Medical School, Ain Shams University, Cairo 11566, Egypt, Department of Clinical Pharmacology, Menoufia Medical School, Menoufia University, Menoufia 32811, Egypt
Published online on: January 20, 2017 https://doi.org/10.3892/etm.2017.4073
Pages: 976-982

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide. It affects the locomotor system, leading to a final severe disability through degeneration of dopaminergic neurons. Despite several therapeutic approaches used, no treatment has been proven to be effective; however, cell therapy may be a promising therapeutic method. In addition, the use of the intranasal (IN) route has been advocated for delivering various therapies to the brain. In the present study, the IN route was used for administration of mesenchymal stem cells (MSCs) in a mouse model of PD, with the aim to evaluate IN delivery as an alternative route for cell based therapy administration in PD. The PD model was developed in C57BL/6 mice using intraperitoneal rotenone administration for 60 consecutive days. MSCs were isolated from the mononuclear cell fraction of pooled bone marrow from C57BL/6 mice and incubated with micrometer‑sized iron oxide (MPIO) particles. For IN administration, we used a 20 µl of 5x105 cell suspension. Neurobehavioral assessment of the mice was performed, and after sacrifice, brain sections were stained with Prussian blue to detect the MPIO‑labeled MSCs. In addition, immunohistochemical evaluation was conducted to detect tyrosine hydroxylase (TH) antibodies in the corpus striatum and dopaminergic neurons in the substantia nigra pars compacta (SNpc). The neurobehavioral assessment revealed progressive deterioration in the locomotor functions of the rotenone group, which was improved following MSC administration. Histopathological evaluation of brain sections in the rotenone+MSC group revealed successful delivery of MSCs, evidenced by positive Prussian blue staining. Furthermore, rotenone treatment led to significant decrease in dopaminergic neuron number in SNpc, as well as similar decrease in the corpus striatum fiber density. By contrast, in animals receiving IN administration of MSCs, the degeneration caused by rotenone treatment was significantly counteracted. In conclusion, the present study validated that IN delivery of MSCs may be a potential safe, easy and cheap alternative route for stem cell treatment in neurodegenerative disorders.

View Figures

View References

1	Chen RC, Chang SF, Su CL, Chen TH, Yen MF, Wu HM, Chen ZY and Liou HH: Prevalence, incidence, and mortality of PD: A door-to-door survey in Ilan county, Taiwan. Neurology. 57:1679–1686. 2001. View Article : Google Scholar : PubMed/NCBI
2	Aarsland D, Londos E and Ballard C: Parkinson's disease dementia and dementia with Lewy bodies: Different aspects of one entity. Int Psychogeriatr. 21:216–219. 2009. View Article : Google Scholar : PubMed/NCBI
3	Samii A, Nutt JG and Ransom BR: Parkinson's disease. Lancet. 363:1783–1193. 2004. View Article : Google Scholar : PubMed/NCBI
4	Sengupta U, Guerrero-Muñoz MJ, Castillo-Carranza DL, Lasagna-Reeves CA, Gerson JE, Paulucci-Holthauzen AA, Krishnamurthy S, Farhed M, Jackson GR and Kayed R: Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biol Psychiatry. 78:672–683. 2015. View Article : Google Scholar : PubMed/NCBI
5	Shulman JM, De Jager PL and Feany MB: Parkinson's disease: Genetics and pathogenesis. Annu Rev Pathol. 6:193–222. 2011. View Article : Google Scholar : PubMed/NCBI
6	Toulouse A and Sullivan AM: Progress in Parkinson's disease-where do we stand? Prog Neurobiol. 85:376–392. 2008. View Article : Google Scholar : PubMed/NCBI
7	Street V and Stacy M: Dopamine agonistsHandbook of Parkinson's Disease. Pahwa R and Lyons KE: 4th. Informa Healthcare; New York, NY: pp. 335–348. 2007
8	Goya R Laguna, Tyers P and Barker RA: The search for a curative cell therapy in Parkinson's disease. J Neurol Sci. 265:32–42. 2008. View Article : Google Scholar : PubMed/NCBI
9	Inden M, Kim D, Qi M, Kitamura Y, Yanagisawa D, Nishimura K, Tsuchiya D, Takata K, Hayashi K, Taniguchi T, et al: Transplantation of mouse embryonic stem cell-derived neurons into the striatum, subthalamic nucleus and substantia nigra, and behavioral recovery in hemiparkinsonian rats. Neurosci Lett. 387:151–156. 2005. View Article : Google Scholar : PubMed/NCBI
10	Hanson LR and Frey WH II: Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 9:(Suppl 3). S52008. View Article : Google Scholar : PubMed/NCBI
11	Chao YX, He BP and Tay SS: Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson's disease. J Neuroimmunol. 216:39–50. 2009. View Article : Google Scholar : PubMed/NCBI
12	Ruigrok MJ and de Lange EC: Emerging insights for translational pharmacokinetic and pharmacokinetic pharmacodynamic studies: Towards prediction of nose-to-brain transport in humans. AAPS J. 17:493–505. 2015. View Article : Google Scholar : PubMed/NCBI
13	de Lange EC: The mastermind approach to CNS drug therapy: Translational prediction of human brain distribution, target site kinetics, and therapeutic effects. Fluids Barriers CNS. 10:122013. View Article : Google Scholar : PubMed/NCBI
14	Djupesland PG, Messina JC and Mahmoud RA: The nasal approach to delivering treatment for brain diseases: An anatomic, physiologic, and delivery technology Overview. Ther Deliv. 5:709–733. 2014. View Article : Google Scholar : PubMed/NCBI
15	Lochhead JJ and Thorne RG: Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 64:614–628. 2012. View Article : Google Scholar : PubMed/NCBI
16	Gambaryan PY, Kondrasheva IG, Severin ES, Guseva AA and Kamensky AA: Increasing the efficiency of Parkinson's disease treatment using a poly (lactic-co-glycolic acid) (PLGA) based L-DOPA delivery system. Exp Neurobiol. 23:246–252. 2014. View Article : Google Scholar : PubMed/NCBI
17	Ji JF, He BP, Dheen ST and Tay SS: Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells. 22:415–427. 2004. View Article : Google Scholar : PubMed/NCBI
18	Sarkar S, Thomas B, Muralikrishnan D and Mohanakumar KP: Effects of serotoninergic drugs on tremor induced by physostigmine in rats. Behav Brain Res. 109:187–193. 2000. View Article : Google Scholar : PubMed/NCBI
19	Haobam R, Sindhu KM, Chandra G and Mohanakumar KP: Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: A comparative study in two mouse strains. Behav Brain Res. 163:159–167. 2005. View Article : Google Scholar : PubMed/NCBI
20	Carlsson T, Winkler C, Lundblad M, Cenci MA, Bjorklund A and Kirik D: Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol Dis. 21:657–668. 2006. View Article : Google Scholar : PubMed/NCBI
21	Blandini F, Cova L, Armentero MT, Zennaro E, Levandis G, Bossolasco P, Calzarossa C, Mellone M, Giuseppe B, Deliliers GL, et al: Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant. 19:203–217. 2010. View Article : Google Scholar : PubMed/NCBI
22	Goya R Laguna, Tyers P and Barker RA: The search for a curative cell therapy in Parkinson's disease. J Neurol Sci. 265:32–42. 2008. View Article : Google Scholar : PubMed/NCBI
23	Paul G: Cell transplantation for patients with Parkinson's disease. Handb Exp Pharmacol. 174:361–388. 2006. View Article : Google Scholar
24	Inden M, Kim DH, Qi M, Kitamura Y, Yanagisawa D, Nishimura K, Tsuchiya D, Takata K, Hayashi K, Taniguchi T, et al: Transplantation of mouse embryonic stem cell-derived neurons into the striatum, subthalamic nucleus and substantia nigra, and behavioral recovery in hemiparkinsonian rats. Neurosci Lett. 387:151–156. 2005. View Article : Google Scholar : PubMed/NCBI
25	Sayles M, Jain M and Barker RA: The cellular repair of the brain in Parkinson's disease-past, present and future. Transpl Immunol. 12:321–342. 2004. View Article : Google Scholar : PubMed/NCBI
26	Chao YX, He BP, Tay SS and Tay W: Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson's disease. J Neuroimmunol. 216:39–50. 2009. View Article : Google Scholar : PubMed/NCBI
27	Dhanda DS, Frey WH II, Leopold D and Kompella UB: Approaches for drug deposition in the human olfactory epithelium. Drug Deliv Technol. 5:64–72. 2005.
28	Thorne RG and Frey WH II: Delivery of neurotrophic factors to the central nervous system: Pharmacokinetic considerations. Clin Pharmacokinet. 40:907–946. 2001. View Article : Google Scholar : PubMed/NCBI
29	Bossolasco P, Cova L, Levandis G, Diana V, Cerri S, Deliliers G Lambertenghi, Polli E, Silani V, Blandini F and Armentero T: Noninvasive near infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson's disease. Int J Nanomedicine. 7:435–447. 2012.PubMed/NCBI
30	Danielyan L, Hammer S Beer, Stolzing A, Schäfer R, Siegel G, Fabian C, Kahle P, Biedermann T, Lourhmati A, Buadze M, et al: Intranasal delivery of bone marrow derived mesenchymal stem cells, macrophages and microglia to the brain in mouse models of Alzheimer's and Parkinson's disease. Cell Transplant. 23:(Suppl 1). S123–S139. 2014. View Article : Google Scholar : PubMed/NCBI
31	Jiang Y, Zhu J, Xu G and Liu X: Intranasal delivery of stem cells to the brain. Expert Opin Drug Deliv. 8:623–632. 2011. View Article : Google Scholar : PubMed/NCBI
32	Dawson T, Mandir A and Lee M: Animal models of PD: Pieces of the same puzzle? Neuron. 35:219–222. 2002. View Article : Google Scholar : PubMed/NCBI
33	Emborg ME: Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J Neurosci Methods. 139:121–143. 2004. View Article : Google Scholar : PubMed/NCBI